$TOVX
Theriva Biologics, Inc.

2024 Q1 Form 10-K Financial Statement

#000141057824000293 Filed on March 25, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.933M $1.321M $6.420M
YoY Change -12.14% -45.41% -15.08%
% of Gross Profit
Research & Development $3.459M $4.196M $14.31M
YoY Change 16.19% 36.68% 22.08%
% of Gross Profit
Depreciation & Amortization $39.00K $39.00K $135.0K
YoY Change 21.88% 30.0% 58.82%
% of Gross Profit
Operating Expenses $5.392M $6.217M $21.43M
YoY Change 4.13% -15.18% -0.7%
Operating Profit -$5.392M -$21.43M
YoY Change 4.13% -0.7%
Interest Expense $227.0K $308.0K $1.442M
YoY Change -38.65% -0.65% 206.81%
% of Operating Profit
Other Income/Expense, Net $227.0K $1.442M
YoY Change -38.65% 206.16%
Pretax Income -$5.165M -$5.909M -$19.99M
YoY Change 7.43% -15.83% -5.31%
Income Tax $0.00 -$424.0K -$1.640M
% Of Pretax Income
Net Earnings -$5.165M -$5.485M -$18.35M
YoY Change 15.34% -1.88% -6.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30 -$1.14
Diluted Earnings Per Share -$0.30 -$0.32 -$1.14
COMMON SHARES
Basic Shares Outstanding 17.15M 17.04M 16.11M
Diluted Shares Outstanding 17.15M 16.11M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.26M $23.18M $23.18M
YoY Change -49.39% -44.54% -44.54%
Cash & Equivalents $18.30M $23.20M $23.18M
Short-Term Investments
Other Short-Term Assets $1.487M $2.286M $2.286M
YoY Change -62.73% -34.69% -34.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables $136.0K $128.0K
Total Short-Term Assets $21.66M $27.40M $27.40M
YoY Change -46.26% -39.8% -39.8%
LONG-TERM ASSETS
Property, Plant & Equipment $375.0K $422.0K $21.94M
YoY Change 15.74% 22.32% 6.02%
Goodwill $5.573M $5.700M
YoY Change -0.78% 3.17%
Intangibles $19.32M $19.76M
YoY Change -0.79% 3.16%
Long-Term Investments
YoY Change
Other Assets $176.0K $180.0K $180.0K
YoY Change 46.67% 50.0% 50.0%
Total Long-Term Assets $27.07M $27.82M $27.82M
YoY Change -1.86% 5.6% 5.6%
TOTAL ASSETS
Total Short-Term Assets $21.66M $27.40M $27.40M
Total Long-Term Assets $27.07M $27.82M $27.82M
Total Assets $48.73M $55.22M $55.22M
YoY Change -28.22% -23.16% -23.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $571.0K $770.0K $770.0K
YoY Change 18.96% -15.85% -16.3%
Accrued Expenses $3.327M $2.995M $4.999M
YoY Change 60.26% 100.2% 60.22%
Deferred Revenue $906.0K
YoY Change
Short-Term Debt $0.00 $63.00K $0.00
YoY Change -100.0% 10.53%
Long-Term Debt Due $62.00K $63.00K $63.00K
YoY Change -11.43% 5.0% 5.0%
Total Short-Term Liabilities $6.009M $6.738M $6.738M
YoY Change -30.28% -4.56% -4.56%
LONG-TERM LIABILITIES
Long-Term Debt $159.0K $162.0K $162.0K
YoY Change -0.63% -26.36% -26.36%
Other Long-Term Liabilities $8.439M $8.622M $8.622M
YoY Change 17.05% 2.64% 2.64%
Total Long-Term Liabilities $8.598M $8.784M $8.784M
YoY Change 16.66% 1.9% 1.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.009M $6.738M $6.738M
Total Long-Term Liabilities $8.598M $8.784M $8.784M
Total Liabilities $14.61M $15.52M $15.52M
YoY Change -15.57% -10.26% -10.28%
SHAREHOLDERS EQUITY
Retained Earnings -$314.5M -$309.3M
YoY Change 6.45% 6.3%
Common Stock $346.7M $346.5M
YoY Change 0.82% 0.81%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K $288.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $34.12M $39.70M $39.70M
YoY Change
Total Liabilities & Shareholders Equity $48.73M $55.22M $55.22M
YoY Change -28.22% -23.16% -23.16%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$5.165M -$5.485M -$18.35M
YoY Change 15.34% -1.88% -6.79%
Depreciation, Depletion And Amortization $39.00K $39.00K $135.0K
YoY Change 21.88% 30.0% 58.82%
Cash From Operating Activities -$4.881M -$6.541M -$19.00M
YoY Change -12.99% 21.81% -0.45%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $56.00K $202.0K
YoY Change -100.0% -37.78% 74.14%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$56.00K -$202.0K
YoY Change -100.0% -37.78% -95.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $75.00K
YoY Change -94.55%
Cash From Financing Activities 0.000 -1.457M 625.0K
YoY Change -100.0% -55.71% -132.38%
NET CHANGE
Cash From Operating Activities -4.881M -6.541M -19.00M
Cash From Investing Activities 0.000 -56.00K -202.0K
Cash From Financing Activities 0.000 -1.457M 625.0K
Net Change In Cash -4.919M -8.054M -18.60M
YoY Change -13.82% -7.95% -26.79%
FREE CASH FLOW
Cash From Operating Activities -$4.881M -$6.541M -$19.00M
Capital Expenditures $0.00 $56.00K $202.0K
Free Cash Flow -$4.881M -$6.597M -$19.20M
YoY Change -13.12% 20.82% 0.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19755000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19150000
CY2023Q4 us-gaap Goodwill
Goodwill
5700000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
CY2023Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
78000
CY2023Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-12584
CY2023 dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Ste. 270
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2023 dei Entity Address Country
EntityAddressCountry
MD
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2023 dei City Area Code
CityAreaCode
301
CY2023 dei Local Phone Number
LocalPhoneNumber
417-4364
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
TOVX
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
16791123000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17148049
CY2023 dei Auditor Firm
AuditorFirmId
243
CY2023 dei Auditor Name
AuditorName
BDO USA, P.C
CY2023 dei Auditor Location
AuditorLocation
Raleigh, North Carolina
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23177000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41786000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1812000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
27403000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
45520000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
102000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
99000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1759000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1199000
CY2022Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2023Q4 us-gaap Assets
Assets
55219000
CY2022Q4 us-gaap Assets
Assets
71861000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
770000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
915000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2995000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1496000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
2973000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
906000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
63000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
57000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6738000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7060000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6274000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7211000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
162000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
221000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1618000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
906000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1442000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1187000
CY2023Q4 us-gaap Liabilities
Liabilities
15522000
CY2022Q4 us-gaap Liabilities
Liabilities
17297000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17868282
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17148049
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844061
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15123828
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
346519000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343750000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-679000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309318000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290969000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36963000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55219000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71861000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7120000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9858000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14311000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11723000
CY2023 us-gaap Operating Expenses
OperatingExpenses
21431000
CY2022 us-gaap Operating Expenses
OperatingExpenses
21581000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-21431000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-21581000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-41000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
1439000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
512000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1442000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
471000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19989000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21110000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1640000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1425000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-18349000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-19685000
CY2023 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
0
CY2022 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18349000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20025000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16107014
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16107014
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15327328
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15327328
CY2023 us-gaap Profit Loss
ProfitLoss
-18349000
CY2022 us-gaap Profit Loss
ProfitLoss
-19685000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
711000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-679000
CY2023 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17638000
CY2022 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20364000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
475000
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
679000
CY2022 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
288000
CY2022 us-gaap Profit Loss
ProfitLoss
-19685000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
552000
CY2023 tovx Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
2219000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-711000
CY2023 us-gaap Profit Loss
ProfitLoss
-18349000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36963000
CY2023 us-gaap Profit Loss
ProfitLoss
-18349000
CY2022 us-gaap Profit Loss
ProfitLoss
-19685000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
552000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
475000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1640000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1425000
CY2023 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-660000
CY2022 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2091000
CY2023 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
1731000
CY2022 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
0
CY2023 tovx Non Cash Lease Expense
NonCashLeaseExpense
388000
CY2022 tovx Non Cash Lease Expense
NonCashLeaseExpense
183000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1368000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
363000
CY2023 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
54000
CY2022 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
0
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-157000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-385000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1470000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-267000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
104000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
333000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-422000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-124000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18996000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19082000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
202000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
116000
CY2023 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
CY2022 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
CY2023 tovx Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
0
CY2022 tovx Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-202000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4396000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
75000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
CY2023 tovx Proceeds From Issuance Under At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceUnderAtMarketOfferingNetOfIssuanceCosts
2219000
CY2022 tovx Proceeds From Issuance Under At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceUnderAtMarketOfferingNetOfIssuanceCosts
0
CY2023 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1519000
CY2022 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
3000000
CY2023 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0
CY2022 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
288000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
625000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1930000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-32000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18606000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25408000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23279000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41885000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23177000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41786000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
102000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
99000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23279000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41885000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023 tovx Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
0
CY2022 tovx Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
11093000
CY2023 tovx Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
0
CY2022 tovx Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
CY2023 tovx Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
0
CY2022 tovx Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
CY2023 tovx Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
0
CY2022 tovx Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
-1061000
CY2023 tovx In Process Research And Development Measurement Period Adjustment
InProcessResearchAndDevelopmentMeasurementPeriodAdjustment
0
CY2022 tovx In Process Research And Development Measurement Period Adjustment
InProcessResearchAndDevelopmentMeasurementPeriodAdjustment
810000
CY2023 tovx Deferred Tax Liability Measurement Period Adjustment
DeferredTaxLiabilityMeasurementPeriodAdjustment
0
CY2022 tovx Deferred Tax Liability Measurement Period Adjustment
DeferredTaxLiabilityMeasurementPeriodAdjustment
202000
CY2023 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
0
CY2022 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
158437840
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15844061
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023 tovx Number Of Subsidiaries
NumberOfSubsidiaries
9
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309318000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23200000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18600000
CY2023 us-gaap Profit Loss
ProfitLoss
-18300000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309300000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23200000
CY2023 tovx Number Of Intangible Assets Generated As Result Of Acquisition
NumberOfIntangibleAssetsGeneratedAsResultOfAcquisition
2
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
CY2023 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
175000
CY2023Q4 us-gaap Goodwill
Goodwill
5700000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, research and development costs, business combinations, contingent consideration, fair value of long-lived assets, warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p>
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85000
CY2022 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2023 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2023Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1700000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
800000
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
1100000
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
2300000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Financial Liabilities
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities
277000
CY2022 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
607000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1119000
CY2022Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2293000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
496000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
637000
CY2023Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
491000
CY2022Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
418000
CY2023Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
180000
CY2022Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
155000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
128000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87000
CY2023Q4 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
0
CY2022Q4 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
144000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1424000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1210000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1002000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
865000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85000
CY2023Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1700000
CY2022Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
807000
CY2023Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
843000
CY2022Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
197000
CY2023Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
452000
CY2022Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
492000
CY2023Q4 tovx Accrued Expenses
AccruedExpenses
2995000
CY2022Q4 tovx Accrued Expenses
AccruedExpenses
1496000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1307000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1216000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
127000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
87000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
83000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
100000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
CY2023 tovx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
0.59
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0402
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M18D
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1300000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
900000
CY2020Q4 tovx Over Allotment Option Period
OverAllotmentOptionPeriod
P45D
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
CY2022 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2023 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price Decrease
PreferredStockConvertibleConversionPriceDecrease
1.22
CY2022 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y9M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
71
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
182
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M10D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
634426
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.22
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2022Q3 tovx Votes Relating To Preferred Stock
VotesRelatingToPreferredStock
1549295
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
63000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
162000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
57000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
221000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
63000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
65000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
54000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
33000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10000
CY2023Q4 tovx Long Term Debt.
LongTermDebt.
225000
CY2022Q4 us-gaap Payments To Employees
PaymentsToEmployees
614250
CY2023Q4 us-gaap Payments To Employees
PaymentsToEmployees
644963
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
22000
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
624000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
569000
CY2023 tovx Non Cash Addition Of Right Of Use Assets
NonCashAdditionOfRightOfUseAssets
937000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
654000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
664000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
582000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
368000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2268000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
339000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1929000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1442000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8568000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15325000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-11421000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5785000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19989000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21110000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1640000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1427000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1640000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1427000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1640000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1425000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4198000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4433000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-532000
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0266
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-678000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0322
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-457000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0229
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-231000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0110
CY2023 tovx Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Foreign Income Tax Rate Differential
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowanceForeignIncomeTaxRateDifferential
1332000
CY2023 tovx Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Foreign Income Tax Rate Differential
IncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceForeignIncomeTaxRateDifferential
-0.0666
CY2022 tovx Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Foreign Income Tax Rate Differential
IncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceForeignIncomeTaxRateDifferential
0.0000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2291000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1146
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2901000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1374
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-187000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0093
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
575000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0272
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
111000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0056
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
441000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0211
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1640000
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0820
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1425000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0675
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27356000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22235000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
24000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
29000
CY2023Q4 tovx Deferred Tax Assets Stocks Issued For Services
DeferredTaxAssetsStocksIssuedForServices
957000
CY2022Q4 tovx Deferred Tax Assets Stocks Issued For Services
DeferredTaxAssetsStocksIssuedForServices
1053000
CY2023Q4 tovx Deferred Tax Assets Stock Issued For Acquisition Of Program
DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
1457000
CY2022Q4 tovx Deferred Tax Assets Stock Issued For Acquisition Of Program
DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
1456000
CY2023Q4 tovx Deferred Tax Assets Stock Issued For License Agreement
DeferredTaxAssetsStockIssuedForLicenseAgreement
1124000
CY2022Q4 tovx Deferred Tax Assets Stock Issued For License Agreement
DeferredTaxAssetsStockIssuedForLicenseAgreement
1362000
CY2023Q4 tovx Deferred Tax Assets Tax Deferred Expense Amortizable License Fee
DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
3000
CY2022Q4 tovx Deferred Tax Assets Tax Deferred Expense Amortizable License Fee
DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
4000
CY2023Q4 tovx Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
2422000
CY2022Q4 tovx Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
1592000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33343000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27731000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28351000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24562000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4992000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3169000
CY2023Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4939000
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4787000
CY2023Q4 tovx Deferred Tax Liabilities Right Of Use Assets Net
DeferredTaxLiabilitiesRightOfUseAssetsNet
53000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4992000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4787000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1618000
CY2023Q4 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000293-index-headers.html Edgar Link pending
0001410578-24-000293-index.html Edgar Link pending
0001410578-24-000293.txt Edgar Link pending
0001410578-24-000293-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20231231.xsd Edgar Link pending
tmb-20231231x10k.htm Edgar Link pending
tmb-20231231x10k001.jpg Edgar Link pending
tmb-20231231x10k002.jpg Edgar Link pending
tmb-20231231xex10d19.htm Edgar Link pending
tmb-20231231xex10d26.htm Edgar Link pending
tmb-20231231xex10d8.htm Edgar Link pending
tmb-20231231xex10d8001.jpg Edgar Link pending
tmb-20231231xex10d8002.jpg Edgar Link pending
tmb-20231231xex10d8003.jpg Edgar Link pending
tmb-20231231xex10d8004.jpg Edgar Link pending
tmb-20231231xex10d8005.jpg Edgar Link pending
tmb-20231231xex10d8006.jpg Edgar Link pending
tmb-20231231xex10d8007.jpg Edgar Link pending
tmb-20231231xex10d8008.jpg Edgar Link pending
tmb-20231231xex10d8009.jpg Edgar Link pending
tmb-20231231xex10d8010.jpg Edgar Link pending
tmb-20231231xex10d8014.jpg Edgar Link pending
tmb-20231231xex10d8017.jpg Edgar Link pending
tmb-20231231xex10d8018.jpg Edgar Link pending
tmb-20231231xex10d8024.jpg Edgar Link pending
tmb-20231231xex10d8026.jpg Edgar Link pending
tmb-20231231xex10d8027.jpg Edgar Link pending
tmb-20231231xex10d8029.jpg Edgar Link pending
tmb-20231231xex10d8033.jpg Edgar Link pending
tmb-20231231xex10d8036.jpg Edgar Link pending
tmb-20231231xex10d8037.jpg Edgar Link pending
tmb-20231231xex10d8038.jpg Edgar Link pending
tmb-20231231xex10d8043.jpg Edgar Link pending
tmb-20231231xex10d8060.jpg Edgar Link pending
tmb-20231231xex10d8063.jpg Edgar Link pending
tmb-20231231xex10d8068.jpg Edgar Link pending
tmb-20231231xex10d8072.jpg Edgar Link pending
tmb-20231231xex19d1.htm Edgar Link pending
tmb-20231231xex21d1.htm Edgar Link pending
tmb-20231231xex23d1.htm Edgar Link pending
tmb-20231231xex31d1.htm Edgar Link pending
tmb-20231231xex32d1.htm Edgar Link pending
tmb-20231231xex4d3.htm Edgar Link pending
tmb-20231231xex97d1.htm Edgar Link pending
tmb-20231231_cal.xml Edgar Link unprocessable
tmb-20231231_def.xml Edgar Link unprocessable
tmb-20231231_lab.xml Edgar Link unprocessable
tmb-20231231_pre.xml Edgar Link unprocessable
tmb-20231231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable